iarjaccIARJACCIARJACC2709-1880https://doi.org/10.47310/iarjacc.2022.v03i02.015Correlation Between S. PSA Levels and SUV max on 68Ga PSMA PET/CT in Prostate Cancer PatientsViperSharmaKunwarShailen Dev SinghGuleriaRishabhChadhaMD, Nuclear Medicine, PGIMER, Chandigarh, IndiaMD, Pharmacology, DRPGMC, Tanda, IndiaMS, ENT, PGIMER, Chandigarh, IndiaBackground: The present study was done to correlate between S. PSA levels and SUV max on 68Ga PSMA PET/CT in Prostate Cancer Patients. Materials and Methods: Forty-four patients with suspected PCa on clinical assessment and/or raised serum PSA levels (>4ng/ml) were prospectively recruited. Patient who underwent prostatic biopsy prior to 68Ga-PSMA PET/CT and mp MRI, deranged renal function tests or coagulogram and refused consent were excluded. Forty-four patients underwent 68Ga-PSMA PET/CT and 33 patients underwent biopsy. Any focal tracer uptake on 68Ga-PSMA PET/CT was regarded as pathological. Histopathology was taken as gold standard. Results: Mean age of patients was 66.61±9.3 years. Malignancy was detected in 16/33 (48.5%) patients who underwent biopsy. In 17/33 (51.5%), no evidence of malignancy was noted. The median and IQR (interquartile range) of S. PSA levels in this group of 33 patients was 13.4±13.9ng/ml. The median and IQR of the SUVmax was 7.5 and 12.85. On statistically evaluation, no significant correlation was observed between S. PSA and SUVmax (r = 0.316, p = 0.073). Conclusions: The present study concluded that there was no significant correlation was observed between S. PSA and SUVmax in prostate cancer patients.